Home
University & Research Institutions

Sector: University & Research Institutions

Your guide to synthetic drug royalty dealmaking

Selling revenue streams is an increasingly important way of monetising pharma innovations

Drug royalty agreements can help Big Pharma overcome patent cliffs, says top dealmaker

Behzad Khosrowshahi, CEO of DRI Healthcare Trust, looks at recent deals the firm has done, explains what makes a transaction attractive and how to get one over the line

France Brevets’ public sector links hindered monetisation efforts, says CEO

As the sovereign patent fund closes down, CEO Didier Patry shares his thoughts with IAM readers on the organisation’s work over the past decade

Latest content

Hub and spoke IP strategies are generating billions of dollars in biopharma

New Crinetics spin-off is more evidence of the growing influence of models designed to monetise non-core life sciences assets

22 October 2021

EU-wide SPCs would make unitary patent system more attractive, says Bayer IP chief

Joerg Thomaier believes unitary supplementary protection certificates should be introduced to coincide with the roll-out of the UPC

21 October 2021

Ranking as Asia’s most innovative economy highlights South Korea’s need for IP value creation

World-beating R&D and patent rates propel country to top of Asia for the first time in annual WIPO study, but Global Innovation Index also shows areas where IP professionals can help it improve further

27 September 2021

NPE litigation in the US bounces back

The Long Read: Sector-by-sector analysis reveals that transport, financial services and networking all recorded triple-digit percentage growth in patent suits filed by non-practising entities between 2018 and 2020, writes IAM data reporter Bridget Diakun

22 September 2021

CAFC overturns $1.2 billion damages in another Section 112 blow for biotech genus IP

Juno Therapeutics and its partner Sloan Kettering Memorial Cancer Center lose out after the Federal Circuit invalidates a key patent under written description rules

02 September 2021

IAM parent company acquires market-leading US patent litigation data and analytics firm

Austin-based Docket Navigator - which also covers trademarks, antitrust and other legal practice areas - becomes a Law Business Research company

25 August 2021

Legal challenges to the PTAB’s NHK-Fintiv discretionary denial regime mount

Life sciences companies are among those leading the way in going to court to get the current rules struck down

20 August 2021

Brazil on the cusp of passing landmark compulsory technology transfer law

Life sciences innovators may be compelled to hand over trade secrets, data and biological materials under legislation that now only requires President Bolsonaro’s signature to become law

19 August 2021

New study shows surge in data-driven and computer-assisted healthcare patents

Boom in digital healthcare and bioinformatics IP requires strategic adjustments in both the life sciences and high-tech arenas

17 August 2021

mRNA IP will be hot property beyond the pandemic

$3.2 billion Sanofi deal is unlikely to be the last as Big Pharma seeks to consolidate its position in the cutting-edge field

12 August 2021

Unlock unlimited access to all IAM content